FDA Sanctions Solo Use of Nasal Spray Antidepressant Spravato
Known under its commercial name Spravato, esketamine is now approved for tackling treatment-resistant depression.
The U.S. Food and Drug Administration has broadened the scope for Spravato, an antidepressant aerosol. It can now be used independently to manage depression symptoms.
Spravato is based on esketamine, which is derived from one of the two enantiomers of the anesthetic ketamine. Originally, it was available for adults suffering from major depressive disorder who had not seen success with at least two other antidepressant prescriptions.
Previously, patients prescribed Spravato were also required to take an oral antidepressant. Now, the FDA has decided it can be utilized alone, following extensive research that revealed Spravato on its own outperformed a placebo. In the first three quarters of 2024, it brought in around $780 million in revenue for Johnson & Johnson, its manufacturer.
Although Spravato is intended for use under the watchful eye of medical professionals, safety concerns remain.
In a statement about this new usage approval, the company addressed the complexity of depression and mentioned potential risks including sedation, dissociation, respiratory issues, and possibilities for abuse and misuse. Therefore, the administration of the drug will continue to occur within certified treatment facilities.
In the United States, major depressive disorder impacts over 20 million adults, with nearly a third finding little success with just oral antidepressants.




Leave a Reply